Kura Oncology (KURA) Assets Average (2011 - 2026)

Kura Oncology (KURA) has 16 years of Assets Average data on file, last reported at $695.5 million in Q1 2026.

• Quarterly Assets Average fell 7.51% year-over-year to $695.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $695.5 million (down 7.51% YoY) and the FY2025 annual result came in at $749.3 million, up 23.94% from the prior year.
• Assets Average was little changed at $695.5 million in Q1 2026 per KURA's latest filing, from $693.9 million in the prior quarter.
• Across five years, Assets Average topped out at $752.0 million in Q1 2025 and bottomed at $441.1 million in Q1 2023.
• The 5-year median for Assets Average is $501.4 million (2024), against an average of $554.9 million.
• The widest annual swing landed in 2022, when Assets Average declined 19.77%; it then surged 49.97% in 2025.
• Tracing KURA's Assets Average over 5 years: stood at $452.1 million in 2022, then climbed by 2.04% to $461.4 million in 2023, then surged by 34.28% to $619.5 million in 2024, then increased by 12.01% to $693.9 million in 2025, then grew by 0.23% to $695.5 million in 2026.
• Per Business Quant, the three latest KURA Assets Average figures stand at $695.5 million (Q1 2026), $693.9 million (Q4 2025), and $665.9 million (Q3 2025).

Peer Comparison